Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 10Active not recruiting 2Terminated 1Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 33Carboplatin 18Cisplatin 15Nivolumab 14Pemetrexed 12Paclitaxel 12Ipilimumab 11atezolizumab 10Gemcitabine 10venetoclax 9Radiotherapy 9Docetaxel 9durvalumab 8Cyclophosphamide 8fludarabine 7Specimen Handling 7Biopsy 7Bevacizumab 7tislelizumab 6enzalutamide 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6tazemetostat 5fludarabine phosphate 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Inotuzumab Ozogamicin × 90 days × Clear all
NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled 11 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡